Related references
Note: Only part of the references are listed.Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
Anastassia Negrouk et al.
ESMO OPEN (2017)
A Review of Fulvestrant in Breast Cancer
Mark R. Nathan et al.
ONCOLOGY AND THERAPY (2017)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
SEOM clinical guidelines in early-stage breast cancer 2015
J. A. Garcia-Saenz et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
M. Dowsett et al.
LANCET (2015)
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Angelo Di Leo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer
Ivana Sestak et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
John F. R. Robertson et al.
BREAST CANCER RESEARCH (2013)
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Rita S. Mehta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Estrogen and Xenoestrogens in Breast Cancer
S. V. Fernandez et al.
TOXICOLOGIC PATHOLOGY (2010)
Share Paper
